We are proud to announce that our clinical site has met the requirements of the Sponsor in the study ALK8700-A301 (Sponsor: Alkermes, www.alkermes.com) regarding patients who entered treatment.
This also means that our centre got the first place in the world in terms of the number of patients who have received treatment with the investigational drug. Our successful cooperation with the company Syneos Health (http://www.syneoshealth.com) enables us to perform activities in that study.

___________________________________________________________

Hanka Hertmanowska, MD, PhD
Outpatient Neurology Clinic
MS Care Centre Clinical Trials Site

—        clinical trials in the field of neurological diseases

—         comprehensive, monitored treatment of multiple sclerosis

—         comprehensive, monitored treatment of Alzheimer’s disease

—         comprehensive neuropsychological consultations

—         neurological consultations – diagnostically difficult neurological

disorders and symptoms: differential diagnosis, treatment program development,

monitoring the course of the disease

—         borreliosis and tick-borne infections in neurological diseases:
          diagnosis and treatment

—         psychiatric consultations: diagnostics and treatment